Abstract
Selected members of the Wnt signaling community met during a 4-day period in October 2018 to discuss the current challenges and opportunities associated with targeting the Wnt pathway for therapeutic benefit. A summary of key points of these discussions is presented in this report.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Publication types
-
Congress
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acyltransferases / antagonists & inhibitors
-
Acyltransferases / metabolism
-
Antineoplastic Agents / therapeutic use*
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Membrane Proteins / antagonists & inhibitors
-
Membrane Proteins / metabolism
-
Molecular Targeted Therapy / methods*
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Tankyrases / antagonists & inhibitors
-
Tankyrases / metabolism
-
Wnt Signaling Pathway / drug effects*
-
beta Catenin / antagonists & inhibitors*
-
beta Catenin / metabolism
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Membrane Proteins
-
beta Catenin
-
Acyltransferases
-
PORCN protein, human
-
Tankyrases